List view / Grid view

Genome Editing

 

article

Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency

18 June 2024 | By ,

As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s…